KR920702723A - 면역활성 펩티드 및 항체와 이것들의 항-알레르기 치료에의 이용 - Google Patents

면역활성 펩티드 및 항체와 이것들의 항-알레르기 치료에의 이용

Info

Publication number
KR920702723A
KR920702723A KR1019910701875A KR910701875A KR920702723A KR 920702723 A KR920702723 A KR 920702723A KR 1019910701875 A KR1019910701875 A KR 1019910701875A KR 910701875 A KR910701875 A KR 910701875A KR 920702723 A KR920702723 A KR 920702723A
Authority
KR
South Korea
Prior art keywords
phe
gly
lys
immunogen
histamine
Prior art date
Application number
KR1019910701875A
Other languages
English (en)
Other versions
KR0181313B1 (ko
Inventor
레이몬드 스탠워쓰 데니스
빅토르 레윈 이안
네이야르 사리타
죤스 발레리
Original Assignee
데레크 리차드 찬들러
내셔날 리서치 디벨로프먼트 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 데레크 리차드 찬들러, 내셔날 리서치 디벨로프먼트 코포레이션 filed Critical 데레크 리차드 찬들러
Publication of KR920702723A publication Critical patent/KR920702723A/ko
Application granted granted Critical
Publication of KR0181313B1 publication Critical patent/KR0181313B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/807—Hapten conjugated with peptide or protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

내용 없음

Description

면역활성 펩티드 및 항체와 이것들의 항-알레르기 치료에의 이용
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 항체의 구조 및 Fab' 및 Fc영역의 위치를 도시한다.
제2도는 IgE항체가 비만세포 또는 호염기성 세포에 결합하는 부위(2a도) 및, "제2수용체"에 접근할 수 있는 IgE의 활성부분에서 "이펙터영역"을 노출시키면서 세포-결합 IgE 항체가 항원과 교차결합되는 과정(2b도)을 도시한다.
제3도는 세포표면 Fc수용체에 결합하는 IgE를 차단하기 위한 펩티드를 나타내는 스트래티지를 도시한다.

Claims (17)

  1. 양이온 N-말단 머리부와 소수성 C-말단 꼬리부를 포함하는 히스타민-방출 펩티드의 잔기와, 상기 펩티드에 대한 항체를 유도하는 한편 그 펩티드에 의한 히스타민 방출을 억제할 수 있는 잔기로 이루어지는 면역원.
  2. 제1항에 있어서, C-말단이 아미드화에 의해 차단되는 것을 특징으로 하는 면역원.
  3. 제1항 또는 2항에 있어서, C-말단이 Phe-Phe 서열을 포함하는 것을 특징으로 하는 면역원.
  4. 제1항, 2항 또는 3항에 있어서, N-말단 머리부가 Lys-Thr-Lys 서열을 포함하는 것을 특징으로 하는 면역원.
  5. 제1항, 2항, 3항 또는 4항에 있어서, N-말단 머리부가 현저하게 비극성이고 비소수성인 2 내지 6개의 아미노산 잔기에 의해 C-말단 꼬리부와 분리되는 것을 특징으로 하는 면역원.
  6. 제5항에 있어서, N-말단 머리부가 Gly-Ser-Gly 서열에 의해 C-말단 꼬리부와 분리되는 것을 특징으로 하는 면역원.
  7. 제1항에 있어서, 히스타미-방출 펩티드의 잔기가 Lys-Thr-Lys-Gly-Ser-Gly-Phe-Val-Phe의 서열을 가지는 것을 특징으로 하는 면역원.
  8. 제1항에 있어서, 히스타민-방출 펩티드, 또는 그것의 아미드화 또는 비-아미드화 히스타민-방출 유사체의 잔기가 Lys-Thr-Lys-Gly-Ser-Gly-Phe-Phe-Arg-Lys-Thr-Lys-Gly-Ser-Gly-Phe-Phe-Lys-Thr-Lys-Gly-Ser-Gly-Phe-Phe-Val-Phe-Ser-Arg, 또는 Lys-Thr-Lys-Gly-Ser-Gly-Phe-Phe-Val의 서열을 특징으로 하는 아미드화 또는 비-아미드화 히스타민-방출 유사체를 가지는 것을 특징으로 하는 면역원.
  9. 제1항, 2항, 3항, 4항, 5항, 6항, 7항 또는 8항에 있어서, 펩티드의 한 분자의 잔기는 히스타민-방출 펩티드의 잔기를 구성하고, 나머지는 항체-유도잔기를 구성하는 중합체 펩티드의 형태인 것을 특징으로 하는 면역원.
  10. 제1항, 2항, 3항, 4항, 5항, 6항, 7항 또는 8항에 있어서, 항체-유도 잔기가 히스타민-방출 펩티드의 포함체의 잔기를 포함하는 것을 특징으로 하는 면역원.
  11. 제1항, 2항, 3항, 4항, 5항, 6항, 7항, 8항, 9항 또는 10항에 있어서, 항-알레르기 치료에 사용하기 위한 것임을 특징으로 하는 면역원.
  12. 제1항, 2항, 3항, 4항, 5항, 6항, 7항, 8항, 9항 또는 10항의 면역원과 보조액으로 이루어지는 알레르기 치료용 조성물.
  13. 제1항, 2항, 3항, 4항, 5항, 6항, 7항 또는 8항에 규정된 히스타민-방출 펩티드에 특이적인 항체 도메인을 포함하는 리간드로서, 상기 항체 도메인은 또한 히스타민 방출에 대한 트리거신호를 포함하는 IgE의 증쇄상에서 아미노산의 서열과 반응하는 것을 특징으로 하는 리간드.
  14. 제13항에 있어서, 단일클론성 항체의 형태인 것을 특징으로 하는 리간드.
  15. 제14항에 있어서, 상기 항체의 Fab' 단편의 형태인 것을 특징으로 하는 리간드.
  16. 제15항에 있어서, 상기 항체의 F(ab')2 단편의 형태인 것을 특징으로 하는 리간드.
  17. 제13항, 14항, 15항 또는 16항에 있어서, 항-알레르기 치료에 사용하기 위한 것을 특징으로 하는 리간드.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910701875A 1989-06-15 1990-06-15 면역활성 펜티드 및 항체와 이것들의 항-알레르기 치료에의 이용 KR0181313B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB8913737.6 1989-06-15
GB898913737A GB8913737D0 (en) 1989-06-15 1989-06-15 A novel anti-allergy treatment
PCT/GB1990/000926 WO1990015878A1 (en) 1989-06-15 1990-06-15 Immunoactive peptides and antibodies and their use in anti-allergy treatment

Publications (2)

Publication Number Publication Date
KR920702723A true KR920702723A (ko) 1992-10-06
KR0181313B1 KR0181313B1 (ko) 1999-04-01

Family

ID=10658467

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910701875A KR0181313B1 (ko) 1989-06-15 1990-06-15 면역활성 펜티드 및 항체와 이것들의 항-알레르기 치료에의 이용

Country Status (18)

Country Link
US (1) US5601821A (ko)
EP (2) EP0403312A1 (ko)
JP (2) JPH04505922A (ko)
KR (1) KR0181313B1 (ko)
AT (1) ATE122401T1 (ko)
CA (1) CA2057860C (ko)
DE (1) DE69019348T2 (ko)
DK (1) DK0477231T3 (ko)
ES (1) ES2073028T3 (ko)
FI (1) FI104723B (ko)
GB (2) GB8913737D0 (ko)
IE (1) IE71677B1 (ko)
NO (1) NO914937L (ko)
NZ (1) NZ234085A (ko)
PH (1) PH30233A (ko)
PT (1) PT94381B (ko)
WO (1) WO1990015878A1 (ko)
ZA (1) ZA904670B (ko)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955076A (en) * 1989-06-15 1999-09-21 Peptide Therapeutics Limited Immunoactive peptides and antibodies and their use in anti-allergy treatment
SE9102808L (sv) * 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
JP3156237B2 (ja) * 1991-12-24 2001-04-16 雪印乳業株式会社 抗ヒトＩｇＥ モノクローナル抗体
US5958708A (en) * 1992-09-25 1999-09-28 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US6066718A (en) * 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
JPH06113881A (ja) * 1992-10-07 1994-04-26 Snow Brand Milk Prod Co Ltd ヒト型モノクローナル抗ペプチド抗体及びこれをコードするｄｎａ
WO1994014463A1 (en) * 1992-12-21 1994-07-07 The Uab Research Foundation Compositions and method for the inhibition of phagocytes
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
JP3795914B2 (ja) * 1993-04-27 2006-07-12 ユナイテッド・バイオメディカル・インコーポレイテッド ワクチン用免疫原性ｌｈｒｈペプチド構築体および合成普遍免疫刺激器
EP0811016A1 (en) * 1994-03-28 1997-12-10 United Biomedical, Inc. Synthetic peptide based immunogens for the treatment of allergy
GB9412714D0 (en) * 1994-06-24 1994-08-17 Lewin Ian V T cill epitopes
GB9416321D0 (en) * 1994-08-12 1994-10-05 Peptide Therapeutics Ltd Peptides and antibodies and their use in treatment of carcinomas
GB9417086D0 (en) * 1994-08-24 1994-10-12 Peptide Therapeutrics Limited Screen for potential therapeutic compounds
GB9422294D0 (en) * 1994-11-04 1994-12-21 Peptide Therapeutics Ltd Peptides for anti-allergy treatment
GB2304347A (en) 1995-08-11 1997-03-19 Boeringer Ingelheim Vetmedica Antigenic preparations
SK284856B6 (sk) 1996-03-01 2006-01-05 Novartis Ag Imunogénna molekula, farmaceutická kompozícia, ligand, spôsob prípravy imunogénnej molekuly a jej použitie
CA2256900A1 (en) * 1996-05-29 1997-12-04 Xiao-Ying Meng Cationic polymer/lipid nucleic acid delivery vehicles
GB9724531D0 (en) 1997-11-19 1998-01-21 Smithkline Biolog Novel compounds
US6913749B2 (en) * 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
US6573372B2 (en) 1999-01-07 2003-06-03 Heska Corporation Feline immunoglobulin E molecules and compositions there of
EP2361635A3 (en) 2000-08-30 2011-09-14 Pfizer Products Inc. Anti IgE vaccines
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
JP2003047482A (ja) * 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
US20030099668A1 (en) 2001-09-14 2003-05-29 Cytos Biotechnology Ag Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
US7279165B2 (en) 2002-07-19 2007-10-09 Cytos Biotechnology Ag Amyloid β1-6 antigen arrays
AU2003262650B2 (en) 2002-08-14 2009-10-29 Macrogenics, Inc. FcgammaRIIB-specific antibodies and methods of use thereof
ATE419008T1 (de) 2004-04-26 2009-01-15 Innate Pharma Adjuvante zusammensetzung und anwendungsverfahren dafür
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
SI2032592T1 (sl) 2006-06-12 2013-10-30 Cytos Biotechnology Ag Postopki za pakiranje oligonukleotidov v virusu-podobne delce RNA bakteriofagov
JP5764290B2 (ja) 2006-06-26 2015-08-19 マクロジェニクス，インコーポレーテッド ＦｃγＲＩＩＢ特異的抗体およびその使用法
EP2401300B1 (en) * 2009-02-25 2018-01-10 Academia Sinica ANTI-C[epsilon]mX ANTIBODIES CAPABLE OF BINDING TO HUMAN mIgE ON B LYMPHOCYTES
WO2013158274A1 (en) 2012-04-20 2013-10-24 Academia Sinica ANTI-MIGE ANTIBODIES THAT BIND TO THE JUNCTION BETWEEN CH4 AND CεMX DOMAINS
US11234445B2 (en) * 2016-03-18 2022-02-01 Genclis Molecular origin of allergy
BR112020008488A2 (pt) 2017-10-31 2020-10-20 Oneness Biotech Co. Ltd. tratamento de doenças alérgicas mediadas por ige
JP7503857B2 (ja) * 2022-04-11 2024-06-21 緑茵生技股▲ふん▼有限公司 抗アレルギー性ペプチド及びその免疫調節と抗アレルギーに用いられる用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2602443A1 (de) * 1975-04-04 1976-10-21 Univ California Biologisch aktive polypeptide
US4171299A (en) * 1975-04-04 1979-10-16 The Regents Of The University Of California Polypeptide agents for blocking the human allergic response
EP0000252B1 (en) * 1977-06-29 1982-02-03 Beecham Group Plc Peptides, pharmaceutical compositions containing the peptides and a process for the preparation of the peptides
US4683292A (en) * 1983-08-12 1987-07-28 Immunetech, Inc. Immunotherapeutic polypeptide agents which bind to lymphocyte immunoglobulin FC receptors
US4579840A (en) * 1983-08-12 1986-04-01 Immunetech Pharmaceuticals Method of blocking immune complex binding to immunoglobulin Fc receptors
JPH02502183A (ja) * 1987-02-20 1990-07-19 インクローン　システムズ、インコーポレーテッド ワクチン処方におけるモノクローナル抗体
CA1336818C (en) * 1987-04-16 1995-08-29 International Institute Of Cellular And Molecular Pathology Treatment of allergy and composition thereof
GB8727045D0 (en) * 1987-11-19 1987-12-23 Research Corp Ltd Immunoglobulin e competitor
JPH0742313B2 (ja) * 1988-03-28 1995-05-10 日立化成工業株式会社 新規ペプチド、その塩及びペプチド性抗アレルギー剤
ATE126540T1 (de) * 1990-05-25 1995-09-15 Peptide Therapeutics Ltd Immunodiagnostische probe für gelenkrheumatismus.
DE4037426A1 (de) * 1990-11-24 1992-05-27 Kali Chemie Pharma Gmbh Piperidinoalkylbenzoxazin- und -thiazin-verbindungen sowie verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel

Also Published As

Publication number Publication date
DK0477231T3 (da) 1995-07-10
KR0181313B1 (ko) 1999-04-01
ES2073028T3 (es) 1995-08-01
AU646808B2 (en) 1994-03-10
FI915891A0 (fi) 1991-12-13
IE902154L (en) 1990-12-15
AU5814890A (en) 1991-01-08
PT94381B (pt) 1996-11-29
DE69019348T2 (de) 1995-09-21
EP0477231A1 (en) 1992-04-01
IE902154A1 (en) 1991-01-02
PT94381A (pt) 1991-02-08
JPH04505922A (ja) 1992-10-15
US5601821A (en) 1997-02-11
NO914937L (no) 1991-12-19
CA2057860A1 (en) 1990-12-16
GB9013478D0 (en) 1990-08-08
IE71677B1 (en) 1997-02-26
JP2000152783A (ja) 2000-06-06
WO1990015878A1 (en) 1990-12-27
PH30233A (en) 1997-02-05
FI104723B (fi) 2000-03-31
NZ234085A (en) 1991-09-25
EP0403312A1 (en) 1990-12-19
DE69019348D1 (de) 1995-06-14
CA2057860C (en) 2000-05-09
GB8913737D0 (en) 1989-08-02
ATE122401T1 (de) 1995-05-15
EP0477231B1 (en) 1995-05-10
NO914937D0 (no) 1991-12-13
ZA904670B (en) 1992-02-26

Similar Documents

Publication Publication Date Title
KR920702723A (ko) 면역활성 펩티드 및 항체와 이것들의 항-알레르기 치료에의 이용
Larsson Immunocytochemistry: theory and practice
Solomon Bence Jones Proteins and Light Chains of Immunoglobulins.
Loukas et al. Receptor for Fc on the surfaces of schistosomes
KR960703942A (ko) 사람 융모막 고나도트로핀의 항원성을 갖는 화합물(Compounds having the antigenicity of hCG)
US6177253B1 (en) Screening methods for the identification of anti-HIV compounds employing a cyclosporine-specific monoclonal antibody that cross-reacts with HIV-1 p24
KR950032279A (ko) 인체의 프로그램된 세포 사멸과 관련 있는 펩티드 및 이를 암호하는 디엔에이(dna)
KR970704461A (ko) Hla 결합 펩티드 및 그의 용도(hla binding peptides and their uses)
Deshmukh et al. Immune responses to small nuclear ribonucleoproteins: antigen-dependent distinct B cell epitope spreading patterns in mice immunized with recombinant polypeptides of small nuclear ribonucleoproteins
Timpl et al. Characterization of conformation independent antigenic determinants in the triple-helical part of calf and rat collagen
Gupta et al. Localization of epitopes for monoclonal antibodies at the N‐terminus of the porcine zona pellucida glycoprotein pZPC
Burt et al. Use of synthetic peptides in the production and characterization of antibodies directed against predetermined specificities in rat immunoglobulin E
RU2001127439A (ru) Пептиды из последовательности Т-вируса и моноспецифические антитела, связывающиеся с ТТ-вирусом
Marchalonis et al. Antigenic cross-reactions among immunoglobulin of diverse vertebrates (elasmobranchs to man) detected using xenoantisera
KR930703444A (ko) 어류 황체화 호르몬-방출 호르몬 동족체
BOST et al. Complementary peptides as interactive sites for protein binding
DE69333511D1 (de) Epstein-barr virus peptide, und antikörper gegen diese peptide
ATE154807T1 (de) Peptide von dem caseinomacropeptid, antikorper dagegen und ihre andwendungen
GB2299994A (en) Equine arteritis virus peptides antibodies and their use in a diagnostic test
Uray et al. Localisation of a protein core‐specific epitope from gastrointestinal mucin (MUC2). The effect of epitope immobilisation on antibody recognition
Williams Jr et al. Differential mapping of Fc gamma-binding and monoclonal antibody-reactive epitopes on gE, the Fc gamma-binding glycoprotein of herpes simplex virus type 1.
Steffen et al. Immunogenicity and specificity of collagen: XII. Demonstration by immunofluorescence and haemagglutination of antibodies with different specificity to human collagen
DE3881275D1 (de) Monoklonaler antikoerper zur selektiven immunologischen bestimmung von intaktem prokollagen peptid (typ iii) und prokollagen (typ iii) in koerperfluessigkeiten.
KR930703445A (ko) 톡소플라스마 곤디(toxoplasma gondii)의 단백질 항원의 클로닝 및 발현
KR940008700A (ko) 사람형 모노클로날 항펩티드 항체 및 이것을 코드하는 dna

Legal Events

Date Code Title Description
A201 Request for examination
N231 Notification of change of applicant
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20031120

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee